Novozymes, ProMetic in Protein Purification Pact | GenomeWeb

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Novozymes and ProMetic Life Sciences today announced a co-marketing alliance for an albumin purification technology based on a synthetic-ligand affinity adsorbent developed by ProMetic's UK subsidiary, ProMetic BioSciences.

The purification technology was designed for the rapid and cost-effective development of Novozymes' albufuse albumin-fusion molecules, the firms said.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: genetic target for urothelial bladder cancer treatment, and more.

At the Conversation, the University of Oxford's Michael Macklay writes that learning genetic risk of disease is a personal decision.

Two dozen scientific organizations have endorsed the March for Science, according to ScienceInsider.

Researchers in Japan describe a chimpanzee with a chromosomal abnormality similar to human Down syndrome, Mashable reports.